Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey. more
Time Frame | INSM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -3.01% | 0.43% | -0.67% |
1-Month Return | 4.88% | 3.96% | 3.04% |
3-Month Return | 34.2% | 10.23% | 6.82% |
6-Month Return | 175.87% | 7.8% | 9.91% |
1-Year Return | 246.33% | 15.8% | 23.86% |
3-Year Return | 176.56% | 15.31% | 23.44% |
5-Year Return | 365.15% | 72.32% | 91.07% |
10-Year Return | 453.73% | 144.59% | 179.01% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 136.47M | 164.41M | 188.46M | 245.36M | 305.21M | [{"date":"2019-12-31","value":44.71,"profit":true},{"date":"2020-12-31","value":53.87,"profit":true},{"date":"2021-12-31","value":61.75,"profit":true},{"date":"2022-12-31","value":80.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 24.21M | 39.87M | 44.15M | 55.13M | 65.57M | [{"date":"2019-12-31","value":36.92,"profit":true},{"date":"2020-12-31","value":60.81,"profit":true},{"date":"2021-12-31","value":67.33,"profit":true},{"date":"2022-12-31","value":84.07,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 112.25M | 124.54M | 144.31M | 190.23M | 239.63M | [{"date":"2019-12-31","value":46.84,"profit":true},{"date":"2020-12-31","value":51.97,"profit":true},{"date":"2021-12-31","value":60.22,"profit":true},{"date":"2022-12-31","value":79.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 82.26% | 75.75% | 76.57% | 77.53% | 78.52% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.09,"profit":true},{"date":"2021-12-31","value":93.09,"profit":true},{"date":"2022-12-31","value":94.26,"profit":true},{"date":"2023-12-31","value":95.45,"profit":true}] |
Operating Expenses | 347.50M | 389.77M | 512.07M | 668.36M | 920.56M | [{"date":"2019-12-31","value":37.75,"profit":true},{"date":"2020-12-31","value":42.34,"profit":true},{"date":"2021-12-31","value":55.63,"profit":true},{"date":"2022-12-31","value":72.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (235.25M) | (265.23M) | (367.76M) | (478.12M) | (709.63M) | [{"date":"2019-12-31","value":-23524500000,"profit":false},{"date":"2020-12-31","value":-26523200000,"profit":false},{"date":"2021-12-31","value":-36776000000,"profit":false},{"date":"2022-12-31","value":-47812300000,"profit":false},{"date":"2023-12-31","value":-70962600000,"profit":false}] |
Total Non-Operating Income/Expense | (46.02M) | (57.02M) | (109.13M) | (28.47M) | (66.08M) | [{"date":"2019-12-31","value":-4602000000,"profit":false},{"date":"2020-12-31","value":-5702000000,"profit":false},{"date":"2021-12-31","value":-10912500000,"profit":false},{"date":"2022-12-31","value":-2847400000,"profit":false},{"date":"2023-12-31","value":-6608300000,"profit":false}] |
Pre-Tax Income | (253.56M) | (292.69M) | (436.41M) | (480.15M) | (747.01M) | [{"date":"2019-12-31","value":-25356000000,"profit":false},{"date":"2020-12-31","value":-29268800000,"profit":false},{"date":"2021-12-31","value":-43641200000,"profit":false},{"date":"2022-12-31","value":-48015100000,"profit":false},{"date":"2023-12-31","value":-74701200000,"profit":false}] |
Income Taxes | 777.00K | 1.40M | (1.76M) | 1.38M | 2.56M | [{"date":"2019-12-31","value":30.41,"profit":true},{"date":"2020-12-31","value":54.87,"profit":true},{"date":"2021-12-31","value":-68.81,"profit":false},{"date":"2022-12-31","value":54.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (254.34M) | (294.09M) | (434.65M) | (481.53M) | (749.57M) | [{"date":"2019-12-31","value":-25433700000,"profit":false},{"date":"2020-12-31","value":-29409000000,"profit":false},{"date":"2021-12-31","value":-43465400000,"profit":false},{"date":"2022-12-31","value":-48153400000,"profit":false},{"date":"2023-12-31","value":-74956700000,"profit":false}] |
Income From Continuous Operations | (254.34M) | (294.09M) | (434.65M) | (481.53M) | (749.57M) | [{"date":"2019-12-31","value":-25433700000,"profit":false},{"date":"2020-12-31","value":-29409000000,"profit":false},{"date":"2021-12-31","value":-43465400000,"profit":false},{"date":"2022-12-31","value":-48153400000,"profit":false},{"date":"2023-12-31","value":-74956700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (254.34M) | (294.09M) | (434.65M) | (481.53M) | (749.57M) | [{"date":"2019-12-31","value":-25433700000,"profit":false},{"date":"2020-12-31","value":-29409000000,"profit":false},{"date":"2021-12-31","value":-43465400000,"profit":false},{"date":"2022-12-31","value":-48153400000,"profit":false},{"date":"2023-12-31","value":-74956700000,"profit":false}] |
EPS (Diluted) | (3.04) | (3.01) | (3.64) | (3.90) | (5.34) | [{"date":"2019-12-31","value":-304,"profit":false},{"date":"2020-12-31","value":-301,"profit":false},{"date":"2021-12-31","value":-364,"profit":false},{"date":"2022-12-31","value":-390,"profit":false},{"date":"2023-12-31","value":-534,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
INSM | |
---|---|
Cash Ratio | 2.38 |
Current Ratio | 2.71 |
Quick Ratio | 2.53 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
INSM | |
---|---|
ROA (LTM) | -24.77% |
ROE (LTM) | -1453.41% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
INSM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.98 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.02 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
INSM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 39.92 |
P/B | 338.80 |
Price/FCF | NM |
EV/R | 39.93 |
EV/Ebitda | NM |
PEG | NM |
Insmed Inc (INSM) share price today is $76.47
Yes, Indians can buy shares of Insmed Inc (INSM) on Vested. To buy Insmed Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INSM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Insmed Inc (INSM) via the Vested app. You can start investing in Insmed Inc (INSM) with a minimum investment of $1.
You can invest in shares of Insmed Inc (INSM) via Vested in three simple steps:
The 52-week high price of Insmed Inc (INSM) is $80.53. The 52-week low price of Insmed Inc (INSM) is $21.92.
The price-to-earnings (P/E) ratio of Insmed Inc (INSM) is
The price-to-book (P/B) ratio of Insmed Inc (INSM) is 338.80
The dividend yield of Insmed Inc (INSM) is 0.00%
The market capitalization of Insmed Inc (INSM) is $13.12B
The stock symbol (or ticker) of Insmed Inc is INSM